SMi are proud to announce that registration is now live for the 7th annual COPD conference, taking place on the 19th & 20th October 2015 at the Holiday Inn Regents Park Hotel in London UK.
SMi's 7th annual conference on COPD will bring together respiratory leaders and scientific pioneers to strengthen knowledge in combinational therapies, new drugs and personalised treatment, whilst keeping attendees at the forefront of scientific breakthroughs to adapt to the growing need for efficiency in the management of exacerbations.
Understanding COPD pulmonary indications through biomarkers and the practicalities of reliable clinical trials will be a major focus as will hearing from a selection of pharmaceutical organisations currently developing scientific trials for COPD includes case studies from Novartis, Mundipharma, Janssen, MedImmune and Bayer.
Key Speakers Include:
Frank Thielmann, Operational Lead, Inhalation New Solids, Novartis Pharma AG
Philip Silkoff, Senior Medical Director, Johnson and Johnson Pharmaceutical Services LLC
Stefano Petruzzelli, Chief Medical Officer and Director, Global Clinical Development, Chiesi Farmaceutici S.p.A
Sanjeeva Dissanayake, Head of Medical Sciences - Respiratory, Mundipharma
Noel Snell, Director of Research, British Lung Foundation
Geoff Down, Chief Medical Officer, Prosonix
Konstantinos Kostikas, Medical Director Respiratory COPD Region Europe, Novartis Pharma
Thomas Schlange, Senior Biomarker Expert, Bayer
Matthew Sleeman, Senior Director of Biology, Respiratory, Inflammation and Autoimmunity, MedImmune
Key Benefits of Attending Include:
Gain insight into formulation developments and the manufacturing of dry powder inhalation products
Evaluate COPD and comorbidities
Learn about "first in class" inhaled drugs for the treatment of COPD and cystic fibrosis
Ascertain the ACOS Definition and characteristics of a grey-zone syndrome, excluded from current asthma and COPD trials
Study the role of lymphoid follicles in COPD Novel delivery and formulation methods
Analyse airway disease endotyping for personalized therapeutics
In addition to the conference there will be an interactive workshop entitled Improving probability of success in COPD drug development, taking place on the 21st October at the Holiday Inn Regents Park Hotel in Central London.
The workshop will be hosted by: Dr. Graham Clarke, Senior Director and Head of Respiratory & Inflammation at the Early Clinical Development unit, Quintiles and Dr Juan Gispert, European Head allergy, Respiratory, infectious Diseases, Vaccines, Medical Science & Strategy, Quintiles
For those who are interested in attending there is currently a £300 early bird rate available online. For more information or to register visit http://www.copd-conference.co.uk/MNT
Sponsored by Quintiles
COPD
19th & 20th October 2015
Holiday Inn Regents Park Hotel, London UK